Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 setmelanotide trial in rare genetic disorders of obesity
NL-OMON49642Phase 2Active, not recruiting
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jun 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of setmelanotide in No canonical full name exists for "genetic obesity.", obesity, Smith-Magenis syndrome (SMS) and 7 more, sponsored by Rhythm Pharmaceuticals. Primary endpoint: Proportion of patients achieving at least 5% body weight reduction. Started Jun 2020; status: active, not recruiting.
02
Drugs
setmelanotide
03
Conditions
No canonical full name exists for "genetic obesity."obesitySmith-Magenis syndrome (SMS)Melanocortin-4 receptor deficiency (MC4RD)SH2B1 deficiency obesity-insulin resistance syndrome
Beyond the preview
Go deeper on NL-OMON49642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49642.